Fusion protein compositions and methods relating to hemostatic therapy
A CBP and VBP polypeptide composition self-organizes into a matrix to enhance platelet and endothelial cell binding, addressing the lack of uniformity and efficacy in existing hemostatic therapies, particularly for trauma-induced bleeding.
Patent Information
- Application Number
- PCT/US2025/039195
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-08-02
- Filing Date
- 2025-07-25
- Publication Date
- 2026-02-05
AI Technical Summary
Existing hemostatic therapies for high volume bleeding, such as those used for trauma patients, are not quick-acting and lack uniformity in dosage control, often relying on large macromolecules that hinder effective hemostatic effects.
A polypeptide composition comprising a collagen-binding peptide (CBP) and a von Willebrand factor binding peptide (VBP) that self-organizes into a matrix promoting platelet and endothelial cell binding, without the need for large scaffolding materials, providing rapid hemostatic effects.
The CBP and VBP polypeptide composition effectively reduces bleeding by forming a matrix that enhances platelet and endothelial cell binding, demonstrating superior hemostatic performance compared to prior art formulations, even in conditions with low platelet counts or clotting disorders.